<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://www.futurefemhealth.com/p/osteoboost-raises-8m-to-scale-fda</loc><news:news><news:publication><news:name>FutureFemHealth</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-15T20:11:11+00:00</news:publication_date><news:title>Osteoboost raises $8m to scale FDA-cleared wearable targeting bone loss in postmenopausal women</news:title></news:news></url><url><loc>https://www.futurefemhealth.com/p/englands-womens-health-strategy-to</loc><news:news><news:publication><news:name>FutureFemHealth</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-15T19:39:18+00:00</news:publication_date><news:title>England's Women's Health Strategy to include £1.5m femtech fund as refresh focuses on patient voice and waiting lists</news:title></news:news></url><url><loc>https://www.futurefemhealth.com/p/muse-deploys-its-portfolio-into-sport</loc><news:news><news:publication><news:name>FutureFemHealth</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-15T06:02:41+00:00</news:publication_date><news:title>💌 Issue 142: Muse deploys its portfolio into sport | ovarian cancer triage | peptides emerge | Eka closes €91m fund</news:title></news:news></url></urlset>